Biotech Stocks ImmunoGen, BeiGene Surge to New Highs

A new stake from Celgene has BeiGene at record highs

Jul 6, 2017 at 10:31 AM
facebook twitter linkedin

Analysts are weighing in on biotech stocks ImmunoGen, Inc. (NASDAQ:IMGN) and BeiGene Ltd (ADR) (NASDAQ:BGNE), as well as coffee giant Starbucks Corporation (NASDAQ:SBUX). Here's a quick roundup of today's bullish brokerage notes on shares of IMGN, BGNE, and SBUX.

RBC Sets Major Price Target for IMGN Stock

ImmunoGen stock is up 8% at $7.88 today, and earlier touched an annual high of $8.04, after RBC raised its rating to "outperform" from "sector perform," while also boosting its price target to $12 from $5. This represents territory not seen for IMGN since January 2016, though the shares are up 281% year-to-date. Short sellers have been piling on amid this surge. Specifically, short interest jumped 18% over the past two reporting periods, and now represents 16% of Immunogen's float. 

BeiGene Stock Hits Record High on Celgene News

BeiGene stock has rallied 15.8% to trade at $60.55, and earlier hit a record high of  $68.67, thanks to news Celgene will buy a stake in the company and help it develop its cancer treatment. BGNE stock has had a great year on the charts, more than doubling in value. Most analysts are already bullish, with all four in coverage rating the stock a "buy" or "strong buy." Just this morning, in fact, Maxim raised its price target to $57 from $52. 

SBUX Stock Dips Despite Bull Note

Starbucks stock is down 0.6% at $57.61, despite a Mizuho Securities analyst reiterating a "buy" recommendation amid signs of "substantial growth in mobile order adoption." However, Muslim groups in Malaysia have aligned with protesters in Indonesia, calling for a boycott of the coffee chain over its support of LGBT rights. SBUX stock touched a record high of $64.87 about a month ago, but has since pulled back to float just above its 200-day moving average. The equity's 14-day Relative Strength Index (RSI) is now at 30 -- on the cusp of oversold territory.

Starbucks sports a Schaeffer's put/call open interest ratio (SOIR) of 1.19, in the 87th percentile of its annual range. This means near-term options traders have rarely been more put-heavy on SBUX stock.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners